Is PXMD or ORGS more profitable?

PaxMedica has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Orgenesis -3,827.81% N/A -130.18%

Which has stronger earnings and valuation, SCPS or PXMD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is SCPS or PXMD more profitable?

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Is CLVR or PXMD more profitable?

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Which has better earnings and valuation, VRPX or PXMD?

PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is VRPX or PXMD more profitable?

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% PaxMedica N/A -3,167.89% -560.35%

Is PXMD or TRVN more profitable?

Trevena's return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Trevena N/A N/A -119.55%

PaxMedica (PXMD) Competitors

$0.0005 0.00 (0.00%)

As of 07/24/2026

Compare

PXMD vs. ORGS, SCPS, CLVR, VRPX, and TRVN

Should you buy PaxMedica stock or one of its competitors? MarketBeat compares PaxMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PaxMedica include Orgenesis (ORGS), Scopus BioPharma (SCPS), Clever Leaves (CLVR), Virpax Pharmaceuticals (VRPX), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does PaxMedica compare to Orgenesis?

PaxMedica (NASDAQ:PXMD) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

PaxMedica has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Orgenesis	Neutral

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, meaning that its share price is 214% more volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PaxMedica has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Orgenesis	-3,827.81%	N/A	-130.18%

Summary

Orgenesis beats PaxMedica on 6 of the 10 factors compared between the two stocks.

How does PaxMedica compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

Scopus BioPharma has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
PaxMedica	Neutral

Summary

Scopus BioPharma beats PaxMedica on 5 of the 6 factors compared between the two stocks.

How does PaxMedica compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

Clever Leaves has higher revenue and earnings than PaxMedica. Clever Leaves is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
PaxMedica	Neutral

Clever Leaves has a beta of 3816.13, meaning that its share price is 381,513% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Summary

Clever Leaves beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and PaxMedica (NASDAQ:PXMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
PaxMedica	N/A	-3,167.89%	-560.35%

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
PaxMedica	Neutral

Virpax Pharmaceuticals has a beta of -16.52, meaning that its stock price is 1,752% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Virpax Pharmaceuticals beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Trevena?

PaxMedica (NASDAQ:PXMD) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Trevena has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PaxMedica has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Trevena's return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Trevena	N/A	N/A	-119.55%

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Trevena	Neutral

Summary

Trevena beats PaxMedica on 6 of the 9 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PXMD vs. The Competition

Export

Metric	PaxMedica	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6K	$975.11M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	0.00	1.53	27.14	23.64
Price / Sales	N/A	105.75	517.06	88.99
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	0.00	8.47	10.28	6.07
Net Income	-$18.29M	-$2.70M	$3.60B	$331.99M
7 Day Performance	N/A	-2.29%	-1.27%	-0.63%
1 Month Performance	N/A	-3.97%	-0.37%	-2.00%
1 Year Performance	N/A	27.39%	18.30%	13.62%

PaxMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PXMD PaxMedica	N/A	$0.00 flat	N/A	+400.0%	$6K	N/A	N/A	2
ORGS Orgenesis	N/A	$0.00 +320.0%	N/A	-96.0%	$22K	$662K	N/A	150
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+66.7%	$21K	N/A	N/A	9
CLVR Clever Leaves	N/A	$0.01 flat	N/A	+3,250.0%	$18K	$17.42M	N/A	560
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-99.5%	$14K	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PaxMedica (PXMD) Competitors

PXMD vs. ORGS, SCPS, CLVR, VRPX, and TRVN

How does PaxMedica compare to Orgenesis?

Summary

How does PaxMedica compare to Scopus BioPharma?

Summary

How does PaxMedica compare to Clever Leaves?

Summary

How does PaxMedica compare to Virpax Pharmaceuticals?

Summary

How does PaxMedica compare to Trevena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PXMD vs. The Competition

PaxMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PaxMedica (PXMD) Competitors

PXMD vs. ORGS, SCPS, CLVR, VRPX, and TRVN

How does PaxMedica compare to Orgenesis?

Which has stronger earnings & valuation, PXMD or ORGS?

Does the media favor PXMD or ORGS?

Which has more volatility & risk, PXMD or ORGS?

Do institutionals and insiders have more ownership in PXMD or ORGS?

Is PXMD or ORGS more profitable?

Summary

How does PaxMedica compare to Scopus BioPharma?

Which has stronger earnings and valuation, SCPS or PXMD?

Is SCPS or PXMD more profitable?

Which has more risk and volatility, SCPS or PXMD?

Do institutionals & insiders hold more shares of SCPS or PXMD?

Does the media favor SCPS or PXMD?

Summary

How does PaxMedica compare to Clever Leaves?

Do insiders and institutionals believe in CLVR or PXMD?

Is CLVR or PXMD more profitable?

Which has preferable earnings and valuation, CLVR or PXMD?

Does the media prefer CLVR or PXMD?

Which has more risk & volatility, CLVR or PXMD?

Summary

How does PaxMedica compare to Virpax Pharmaceuticals?

Is VRPX or PXMD more profitable?

Does the media favor VRPX or PXMD?

Which has more volatility and risk, VRPX or PXMD?

Which has better earnings and valuation, VRPX or PXMD?

Do institutionals and insiders hold more shares of VRPX or PXMD?

Summary

How does PaxMedica compare to Trevena?

Which has more volatility & risk, PXMD or TRVN?

Do institutionals & insiders hold more shares of PXMD or TRVN?

Which has higher valuation and earnings, PXMD or TRVN?

Is PXMD or TRVN more profitable?

Does the media favor PXMD or TRVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PXMD vs. The Competition

PaxMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools